723 related articles for article (PubMed ID: 18535154)
1. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
[TBL] [Abstract][Full Text] [Related]
2. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.
Levy YS; Bahat-Stroomza M; Barzilay R; Burshtein A; Bulvik S; Barhum Y; Panet H; Melamed E; Offen D
Cytotherapy; 2008; 10(4):340-52. PubMed ID: 18574767
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats.
Ben-Hur T; Idelson M; Khaner H; Pera M; Reinhartz E; Itzik A; Reubinoff BE
Stem Cells; 2004; 22(7):1246-55. PubMed ID: 15579643
[TBL] [Abstract][Full Text] [Related]
4. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease.
Kim JH; Auerbach JM; Rodríguez-Gómez JA; Velasco I; Gavin D; Lumelsky N; Lee SH; Nguyen J; Sánchez-Pernaute R; Bankiewicz K; McKay R
Nature; 2002 Jul; 418(6893):50-6. PubMed ID: 12077607
[TBL] [Abstract][Full Text] [Related]
5. Stem cell-based therapy for Parkinson's disease.
Correia AS; Anisimov SV; Li JY; Brundin P
Ann Med; 2005; 37(7):487-98. PubMed ID: 16278162
[TBL] [Abstract][Full Text] [Related]
6. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease.
O'Keeffe FE; Scott SA; Tyers P; O'Keeffe GW; Dalley JW; Zufferey R; Caldwell MA
Brain; 2008 Mar; 131(Pt 3):630-41. PubMed ID: 18202103
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior.
Park S; Kim E; Koh SE; Maeng S; Lee WD; Lim J; Shim I; Lee YJ
Brain Res; 2012 Jul; 1466():158-66. PubMed ID: 22634376
[TBL] [Abstract][Full Text] [Related]
8. Autologous neural stem cell transplantation: a new treatment option for Parkinson's disease?
Arias-Carrión O; Yuan TF
Med Hypotheses; 2009 Nov; 73(5):757-9. PubMed ID: 19467573
[TBL] [Abstract][Full Text] [Related]
9. Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease.
Parish CL; Parisi S; Persico MG; Arenas E; Minchiotti G
Stem Cells; 2005 Apr; 23(4):471-6. PubMed ID: 15790767
[TBL] [Abstract][Full Text] [Related]
10. Pattern of long-term sensorimotor recovery following intrastriatal and--accumbens DA micrografts in a rat model of Parkinson's disease.
Falkenstein G; Rosenthal C; Reum T; Morgenstern R; Döbrössy M; Nikkhah G
J Comp Neurol; 2009 Jul; 515(1):41-55. PubMed ID: 19399892
[TBL] [Abstract][Full Text] [Related]
11. Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease.
Hahn M; Timmer M; Nikkhah G
J Neurosci Res; 2009 Jul; 87(9):2006-19. PubMed ID: 19235889
[TBL] [Abstract][Full Text] [Related]
12. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Niles LP
J Pineal Res; 2007 Oct; 43(3):245-54. PubMed ID: 17803521
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model.
Gu S; Huang H; Bi J; Yao Y; Wen T
Brain Res; 2009 Feb; 1257():1-9. PubMed ID: 19111525
[TBL] [Abstract][Full Text] [Related]
14. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
Isacson O; Bjorklund LM; Schumacher JM
Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
[TBL] [Abstract][Full Text] [Related]
15. Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: results from an in vitro model system.
McKay BS; Goodman B; Falk T; Sherman SJ
Exp Neurol; 2006 Sep; 201(1):234-43. PubMed ID: 16764861
[TBL] [Abstract][Full Text] [Related]
16. The search for a curative cell therapy in Parkinson's disease.
Laguna Goya R; Tyers P; Barker RA
J Neurol Sci; 2008 Feb; 265(1-2):32-42. PubMed ID: 17936303
[TBL] [Abstract][Full Text] [Related]
17. Dopamine neurons derived from embryonic stem cells efficiently induce behavioral recovery in a Parkinsonian rat model.
Cho YH; Kim DS; Kim PG; Hwang YS; Cho MS; Moon SY; Kim DW; Chang JW
Biochem Biophys Res Commun; 2006 Mar; 341(1):6-12. PubMed ID: 16412382
[TBL] [Abstract][Full Text] [Related]
18. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease.
Riaz SS; Bradford HF
Prog Neurobiol; 2005 Jul; 76(4):257-78. PubMed ID: 16256257
[TBL] [Abstract][Full Text] [Related]
19. Regenerative medicine in Parkinson's disease: generation of mesencephalic dopaminergic cells from embryonic stem cells.
Taylor H; Minger SL
Curr Opin Biotechnol; 2005 Oct; 16(5):487-92. PubMed ID: 16143504
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease.
Quinn M; Mukhida K; Sadi D; Hong M; Mendez I
Eur J Neurosci; 2008 Jan; 27(1):43-52. PubMed ID: 18093176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
